MDP
Madelyn D. Purcell Portfolio
Invests via Pfizer Inc | Managed by Madelyn D. Purcell
Invests via Pfizer Inc
Managed by Madelyn D. Purcell
Automatically Tracked
Madelyn D. Purcell Profile
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Investment Philosophy & Strategy
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-1.49%
Gain -0.02%
Monthly
-0.08%
Yearly
-0.97%
Drawdown
14.56%
$217.34M
Equity
Holdings
$217.34M
Investment
$241.35M
-$39.64M
Profit -$479,819.4
Realized
-$15.62M
Unrealized
-$24.01M
Dividends
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-0.02%
Profit
-$479,819.4
Win %
55%
This Week
Compared To Last Week
Gain
-0.22%
Profit
-$479,819.4
Win %
55%
This Month
Compared to last month
Gain
-1.97%
Profit
-$4.36M
Win %
55%
This Year
Compared to last year
Gain
-12.6%
Profit
-$31.32M
Win %
62%
ZNTL Zentalis Pharmaceuticals, Inc.
+11.82%
+$515,070.36 
BHVN Biohaven Ltd.
+8.96%
+$642,169.15 
PYXS Pyxis Oncology, Inc.
+5.83%
+$914,260.1 
BOLT Bolt Biotherapeutics Inc.
+5.49%
+$7,200.15 
ZURA Zura Bio Ltd.
+3.81%
+$567,782.6 
WVE Wave Life Sciences Ltd.
+2.65%
+$281,250 
CRDF Cardiff Oncology Inc.
+1.15%
+$24,115.75 
SPRO Spero Therapeutics Inc.
+0.64%
+$23,623.48 
CELC Celcuity Inc.
+0.1%
+$26,608.68 
ALLO Allogene Therapeutics Inc.
0%
$0 
ORIC Oric Pharmaceuticals Inc.
0%
$0 
DNA Ginkgo Bioworks Holdings Inc.
-4.58%
-$1,112.64 
NXTC NextCure, Inc.
-2.92%
-$27,603.72 
AGMB Agomab Therapeutics NV
-2.27%
-$21,000 
QTTB Q32 Bio Inc.
-1.05%
-$16,258.88 
CRBU Caribou Biosciences, Inc.
-0.6%
-$46,904.31 
SENS Senseonics Holdings, Inc.
-0.58%
-$65.13 
ARVN Arvinas Inc.
-0.25%
-$69,156.3 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 35 | Longs Won 16/35 45% | Profit Factor 0.71 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $12.68M |
| Average Win $6.11M | Best Trade (Dec 30) $35.05M | Sharpe Ratio -70.71 |
| Average Loss -$7.23M | Worst Trade (Jul 19) -$38.59M | Z-Score 1.77 (92.38%) |
| Commissions $0 | Avg. Trade Length 1y 1m 1w 3d | Expectancy -$1.13M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 30 | 27 | 24 | 21 | 18 | 15 | 12 | 9 | 6 | 3 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
